-
年龄<21岁,发烧i,有炎症的实验室证据ii和需要住院治疗临床严重疾病的证据,涉及多系统(> 2)器官受累(心脏、肾脏、呼吸系统、血液、胃肠道、皮肤病或神经系统); 和 -
没有其他合理的诊断方法;和 -
通过RT-PCR,血清学或抗原检测证实,正在或者近期有过新冠病毒感染;或在症状发作前4周内有COVID-19暴露
ii包括但不限于以下一项或多项:以下指标升高:C反应蛋白(CRP)、红细胞沉降率(ESR) )、纤维蛋白原、降钙素、d-二聚体、铁蛋白、乳酸脱氢酶(LDH)或白介素6(IL-6)。中性粒细胞升高;淋巴细胞减少和白蛋白降低。
-
部分患儿可能符合川崎病的全部或部分标准,但如果他们也符合MIS-C病例 定义,则应报告; -
有SARS-CoV-2感染证据的任何小儿死亡病例均应考虑到MIS-C诊断。
-
An individual aged <21 years presenting with feveri, laboratory evidence of inflammationii, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND -
No alternative plausible diagnoses; AND -
Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms
iiIncluding, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin
-
Some individuals may fulfill full or partial criteria for Kawasaki disease but should be reported if they meet the case definition for MIS-C -
Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection
报告方式: